BiotechTube

DESF + Epinephrine Injection

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergic Reaction

Conditions

Allergic Reaction

Trial Timeline

Jul 17, 2024 → Oct 13, 2024

NCT ID
NCT06527937

About DESF + Epinephrine Injection

DESF + Epinephrine Injection is a phase 2 stage product being developed by Aquestive Therapeutics for Allergic Reaction. The current trial status is completed. This product is registered under clinical trial identifier NCT06527937. Target conditions include Allergic Reaction.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06527937Phase 2Completed

Competing Products

20 competing products in Allergic Reaction

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
25
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
Lesigercept + PlaceboYuhanPhase 2
52
YH35324 + Omalizumab + PlaceboYuhanPhase 1
33
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Prednisolone + VoriconazoleCiplaPhase 2/3
65
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
85
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
33
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
DSP-3025 + PlaceboSumitomo PharmaPhase 1
33
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77

Other Products from Aquestive Therapeutics

Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight categoryPhase 3
69
Riluzole Oral Soluble film (ROSF) 50 mgPhase 2
44
Diazepam Buccal FilmPhase 2
44
Diazepam Buccal Film 12.5 mgPhase 2
44
Riluzole Oral Soluble FilmPhase 2
44